Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-016721
Filing Date
2023-05-12
Accepted
2023-05-12 17:01:01
Documents
45
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 791086
2 ex10-2.htm EX-10.2 8738
3 ex10-3.htm EX-10.3 10634
4 ex31-1.htm EX-31.1 17674
5 ex31-2.htm EX-31.2 18221
6 ex32-1.htm EX-32.1 7218
7 ex32-2.htm EX-32.2 7169
  Complete submission text file 0001493152-23-016721.txt   4008948

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE immx-20230331.xsd EX-101.SCH 27292
9 XBRL CALCULATION FILE immx-20230331_cal.xml EX-101.CAL 32972
10 XBRL DEFINITION FILE immx-20230331_def.xml EX-101.DEF 132129
11 XBRL LABEL FILE immx-20230331_lab.xml EX-101.LAB 286802
12 XBRL PRESENTATION FILE immx-20230331_pre.xml EX-101.PRE 211788
39 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 498923
Mailing Address 10573 W. PICO BLVD. #58 LOS ANGELES CA 90064
Business Address 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES CA 90064 (888) 958-1084
Immix Biopharma, Inc. (Filer) CIK: 0001873835 (see all company filings)

EIN.: 454869378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41159 | Film No.: 23916830
SIC: 2834 Pharmaceutical Preparations